- Home
- RAPT vs ADCT Comparison
RAPT vs ADCT Comparison
Compare RAPT & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAPT
- ADCT
- Stock Information
- Founded
- RAPT 2015
- ADCT 2011
- Country
- RAPT United States
- ADCT Switzerland
- Employees
- RAPT N/A
- ADCT N/A
- Industry
- RAPT Biotechnology: Pharmaceutical Preparations
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- RAPT Health Care
- ADCT Health Care
- Exchange
- RAPT Nasdaq
- ADCT Nasdaq
- Market Cap
- RAPT 498.4M
- ADCT 454.5M
- IPO Year
- RAPT 2019
- ADCT 2020
- Fundamental
- Price
- RAPT $28.83
- ADCT $3.97
- Analyst Decision
- RAPT Strong Buy
- ADCT Strong Buy
- Analyst Count
- RAPT 9
- ADCT 6
- Target Price
- RAPT $57.00
- ADCT $7.60
- AVG Volume (30 Days)
- RAPT 778.5K
- ADCT 745.9K
- Earning Date
- RAPT 11-06-2025
- ADCT 11-10-2025
- Dividend Yield
- RAPT N/A
- ADCT N/A
- EPS Growth
- RAPT N/A
- ADCT N/A
- EPS
- RAPT N/A
- ADCT N/A
- Revenue
- RAPT N/A
- ADCT $75,209,000.00
- Revenue This Year
- RAPT N/A
- ADCT $11.78
- Revenue Next Year
- RAPT N/A
- ADCT $4.83
- P/E Ratio
- RAPT N/A
- ADCT N/A
- Revenue Growth
- RAPT N/A
- ADCT 6.35
- 52 Week Low
- RAPT $5.67
- ADCT $1.05
- 52 Week High
- RAPT $42.39
- ADCT $4.80
- Technical
- Relative Strength Index (RSI)
- RAPT 53.26
- ADCT 45.58
- Support Level
- RAPT $27.76
- ADCT $3.87
- Resistance Level
- RAPT $29.90
- ADCT $4.19
- Average True Range (ATR)
- RAPT 1.66
- ADCT 0.30
- MACD
- RAPT -0.46
- ADCT -0.05
- Stochastic Oscillator
- RAPT 41.72
- ADCT 27.78
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).